Physician profile
Howard Grattan
NPI 1902973266
$4,556.58
in general payments reported to CMS, 2019-2025
27 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 81% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $466 · 2021: $601 · 2022: $342 · 2023: $226 · 2024: $353 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Travel and Lodging: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.78 |
| Travel and Lodging | $1,036.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,021.58 | 2019-2025 | Proclaim, Eterna, Axium |
| Abbvie INC. | $428.93 | 2021-2023 | |
| Nevro Corp. | $285.90 | 2019-2022 | |
| Allergan, INC. | $266.70 | 2019-2022 | |
| Pfizer INC. | $184.91 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $184.62 | 2019-2025 | Belbuca |
| Amgen INC. | $123.34 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.90 | 2020-2024 | Relistor |
| Novartis Pharmaceuticals Corporation | $88.47 | 2019-2021 | |
| Lilly USA, LLC | $87.36 | 2019-2022 | |
| Boston Scientific Corporation | $83.51 | 2021-2025 | General - Pain Management |
| Daiichi Sankyo INC. | $79.39 | 2019 | |
| Eisai INC. | $77.02 | 2020-2021 | |
| Medtronic, INC. | $74.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $73.02 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $53.85 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $49.75 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $49.35 | 2021 | |
| Biotronik Nro, INC. | $42.32 | 2025 | Prospera |
| Si-Bone, INC. | $33.03 | 2021-2024 | |
| Medtronic USA, INC. | $27.37 | 2020 | |
| Saluda Medical Americas, INC. | $26.07 | 2025 | Evoke |
| Bioventus LLC | $24.17 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.05 | 2019 | |
| Pacira Therapeutics, INC. | $19.70 | 2020 | |
| Assertio Therapeutics, INC. | $19.35 | 2019 | |
| Stimwave Technologies Incorporated | $9.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Grattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.